background
exhal
breath
condens
ebc
sampl
consid
invent
novel
method
isol
respiratori
virus
method
studi
volunt
experienc
upper
airway
infect
recruit
winter
earli
spring
first
half
winter
ninetynin
ebc
success
obtain
screen
commonli
circul
respiratori
virus
investig
effici
viru
isol
ebc
nasal
swab
taken
parallel
subset
volunt
combin
use
ecov
devic
allow
registr
exhal
volum
breath
frequenc
collect
way
number
exhal
viral
particl
per
liter
air
per
minut
theoret
estim
result
viral
screen
result
detect
differ
virus
ebc
andor
nasal
swab
rhinoviru
human
respiratori
syncyti
viru
b
influenza
influenza
b
rhinoviru
detect
ebc
ebc
influenza
b
posit
report
viral
detect
rate
ebc
much
lower
detect
rate
observ
use
nasal
swab
conclus
although
promis
ebc
collect
use
reliabl
diagnosi
respiratori
infect
human
respiratori
tract
infect
repres
commonli
encount
infect
worldwid
major
case
etiolog
infect
remain
undetermin
due
rapid
convalesc
infect
respiratori
tract
infect
healthi
adult
caus
varieti
pathogen
detect
agent
current
base
isol
nasal
swab
ns
bronchoalveolar
lavag
bal
nasopharyng
aspir
sputum
sampl
acquisit
specimen
semiinvas
invas
techniqu
often
unpleas
patient
therefor
exhal
breath
condens
ebc
analysi
recent
explor
new
noninvas
method
monitor
lung
inflamm
pulmonari
diseas
chronic
obstruct
pulmonari
diseas
copd
asthma
cystic
fibrosi
lung
cancer
etc
ebc
mainli
consist
water
vapour
small
fraction
contain
respiratori
droplet
deriv
airway
line
fluid
observ
creat
grow
interest
use
ebc
new
sampl
method
screen
respiratori
virus
infect
upper
airway
first
investig
suspect
turbul
inhal
air
respons
aerosolis
respiratori
fluid
howev
effect
turbul
airflow
limit
upper
airway
sinc
turbul
airflow
becom
laminar
reach
smaller
bronchial
airway
alveoli
recent
bronchiol
fluid
film
burst
model
describ
model
suggest
aerosol
produc
inhal
burst
fluid
bubbl
present
bronchiol
aim
studi
investig
whether
ebc
collect
method
suit
effici
condens
aerosolis
viru
particl
normal
breath
explor
isol
respiratori
virus
condens
therefor
screen
ebc
sampl
viru
specif
pcr
assay
target
studi
ebc
collect
otherwis
healthi
volunt
show
respiratori
flulik
symptom
defin
tabl
use
commerci
avail
condens
respiratori
research
inc
charlottesvil
virginia
usa
patient
instruct
breath
oral
tidal
volum
mouthpiec
attach
condens
minut
nose
clip
use
collect
saliva
contamin
avoid
presenc
oneway
valv
tshape
section
mouthpiec
first
part
studi
start
winter
spring
ebc
sampl
collect
patient
voluntari
present
laboratori
major
volunt
student
respond
inform
leaflet
distribut
univers
build
cathol
univers
leuven
sampl
collect
aluminium
cooler
sleev
chill
fall
first
half
winter
condens
collect
patient
present
gener
practition
due
practic
circumst
condens
collect
cooler
chill
collect
connect
custom
made
connectingpiec
ecov
jaeger
germani
devic
regist
ventilatori
paramet
exhal
volum
breath
frequenc
tidal
volum
addit
ns
obtain
parallel
condens
collect
patient
ebc
immedi
store
nasal
swab
ns
refriger
viral
dna
rna
extract
ebc
sampl
nasal
swab
store
three
specimen
exclud
studi
due
incorrect
condens
collect
short
questionnair
use
document
date
birth
sever
respiratori
complaint
record
day
symptomat
ill
volunt
studi
approv
medic
ethic
committe
univers
hospit
leuven
inform
consent
receiv
particip
viral
dna
rna
isol
qiaamp
minelut
viru
kit
qiagen
westburg
netherland
accord
instruct
manual
ebc
extract
elut
elut
buffer
ns
extract
elut
buffer
breath
condens
screen
respiratori
rna
virus
cov
rv
hmpv
infa
b
use
onestep
rtpcr
kit
qiagen
westburg
netherland
reaction
contain
extract
rna
forward
revers
primer
tabl
one
step
enzym
mix
one
step
rtpcr
buffer
dntp
adenoviru
screen
dna
pcr
carri
amplif
reaction
mix
contain
forward
primer
adfw
revers
primer
adrv
mm
dntp
buffer
c
u
taq
polymeras
final
volum
pcr
primer
use
locat
conserv
region
genom
respiratori
pathogen
tabl
reaction
carri
thermocycl
westburg
leusden
netherland
initi
revers
transcript
step
rna
virus
min
follow
pcr
activ
cycl
amplif
follow
final
extens
step
min
dna
amplif
program
initi
denatur
step
min
follow
cycl
final
extens
step
min
amplicon
subject
polyacrylamid
gel
visualis
uv
light
stain
ethidium
bromid
pcr
product
purifi
use
invitek
msb
spin
pcrapac
kit
cycl
sequenc
forward
revers
direct
use
abi
prism
bigdy
termin
cycl
sequenc
readi
reaction
kit
appli
biosystem
foster
citi
ca
usa
sequenc
analysi
perform
genet
analys
appli
biosystem
foster
citi
ca
usa
consensu
sequenc
obtain
use
seqman
ii
softwar
dnastar
madison
wi
sampl
hrsv
detect
use
rtpcr
assay
previous
describ
brief
multiplex
mix
prepar
final
volum
use
extract
rna
eurogentec
onestep
revers
transcriptas
qpcr
master
mix
contain
rox
passiv
refer
euroscript
rt
rnase
inhibitor
eurogentec
sera
belgium
nm
hrsva
b
specif
forward
revers
primer
nm
hrsva
b
mgb
probe
crna
standard
construct
use
megashortscript
kit
ambion
austin
tx
usa
spectrophotometr
quantifi
viral
load
rv
posit
sampl
quantifi
qrtpcr
describ
manuscript
publish
lu
cowork
eurogentec
onestep
revers
transcriptas
qpcr
kit
use
prepar
master
mix
describ
primerset
hrsvaf
f
ctgtgatagarttccaacaaaagaaca
hrsvaf
f
agttacacctgcattaacactaaattcc
hrsvbn
n
ggctccagaatataggcatgattc
hrsvbn
n
tggttattacaagaagagcagctatacacagt
mgb
probe
probe
locat
ad
final
concentr
respect
crna
standard
construct
base
pcr
product
sampl
use
megascript
kit
ambion
austin
tx
usa
quantif
perform
spectrophotomet
nm
convert
molecul
number
tenfold
serial
dilut
allow
detect
rang
rna
copi
use
rtpcr
assay
carri
abi
prism
sequenc
detect
system
appli
biosystem
foster
citi
ca
usa
initi
revers
transcript
step
perform
min
follow
denatur
step
min
final
amplif
step
cycli
sec
min
complet
men
median
age
rang
year
age
gender
miss
particip
second
group
total
particip
year
old
younger
year
old
older
year
total
patient
alreadi
feel
ill
day
day
sampl
obtain
seven
volunt
symptomat
day
particip
alreadi
ill
day
day
sampl
collect
data
durat
symptom
lack
patient
almost
volunt
experienc
least
symptom
except
two
patient
tabl
fortyseven
volunt
complain
constant
runni
stuffi
nose
frequent
sneez
event
particip
seriou
sore
throat
tabl
first
part
studi
collect
ebc
screen
ebc
respiratori
virus
tabl
show
rv
posit
sampl
tabl
second
part
collect
ebc
patient
present
gener
practition
two
ebc
posit
one
investig
respiratori
virus
rv
infb
inspect
detect
rate
respiratori
virus
condens
ns
taken
second
group
volunt
comparison
ns
one
viral
pathogen
isol
viral
screen
ns
result
detect
rv
infa
subtyp
hrsvb
quantif
hrsvb
viral
load
demonstr
sampl
viral
titer
rna
copiesml
rna
copiesml
respect
rv
rtpcr
assay
allow
quantif
sampl
test
posit
rv
pcr
tabl
presenc
pathogen
ebc
ns
confirm
sampl
sampl
test
posit
rv
ebc
ns
sampl
rv
detect
ns
analysi
ebc
demonstr
infb
infect
ebc
sampl
collect
fall
winter
measur
ecov
tabl
sampl
posit
infb
use
combin
ecov
theori
viral
gener
rate
number
viral
rna
copi
exhal
per
minut
predict
quantif
exhal
viral
load
estim
rna
copi
per
litr
exhal
air
per
minut
calcul
quantif
exhal
infb
would
allow
us
predict
gener
rate
viru
due
insuffici
sampl
volum
could
determin
number
rna
copi
sampl
collect
exhal
breath
condens
novel
noninvas
method
obtain
sampl
upper
respiratori
tract
collect
ebc
easi
perform
conduct
home
environ
method
much
agreeabl
patient
compar
unpleas
invas
collect
nasal
swab
bal
aspir
etc
aspect
render
method
attract
routin
laboratori
diagnost
viral
infect
studi
perform
breath
analys
viral
detect
use
modifi
face
mask
remov
central
region
electret
remov
teflon
filter
exhal
particl
impact
collect
devic
aerosol
particl
airway
line
fluid
precipit
condens
breath
cool
serv
immedi
start
point
molecular
test
studi
largest
subset
volunt
investig
ebc
specimen
detect
respiratori
virus
previou
studi
report
inclus
limit
subset
particip
investig
presenc
limit
number
virus
breath
sampl
studi
perform
fabian
colleagu
includ
volunt
huynh
cowork
recruit
volunt
exhal
breath
sampl
studi
stelzerbraid
et
al
ebc
analys
stgeorg
et
al
report
particip
adult
studi
focus
detect
infa
b
hrsv
hmpv
screen
sampl
panel
commonli
circul
respiratori
virus
base
analysi
ebc
ebc
exclud
result
support
exhal
rv
infb
sampl
sinc
mani
volunt
alreadi
experienc
symptom
day
initi
presum
alreadi
recov
infect
longer
exhal
viru
common
cold
infect
suggest
person
may
alreadi
infecti
day
experienc
symptom
howev
second
part
studi
start
collect
ebc
parallel
nasal
swab
patient
present
medic
doctor
day
onset
symptom
condens
pathogen
detect
ebc
ns
detect
rate
respiratori
viral
pathogen
ns
much
higher
detect
rate
ebc
low
detect
viru
posit
condens
therefor
attribut
fact
volunt
longer
infecti
discrep
detect
rate
sampl
may
also
explain
differ
sever
respiratori
infect
sinc
compar
sampl
differ
part
respiratori
tract
patient
deliv
posit
ns
may
possibl
suffer
upper
airway
infect
wherea
ebc
posit
volunt
may
experienc
advanc
lower
respiratori
tract
infect
howev
effect
nasal
inhal
ebc
collect
guid
form
particl
upper
respiratori
tract
lower
compart
stead
oral
inhal
investig
patient
posit
ebc
sampl
experienc
symptom
maximum
two
day
time
collect
howev
differ
patient
posit
ns
six
patient
provid
posit
ns
experienc
symptom
longer
period
time
collect
tabl
group
volunt
provid
ebc
neg
ebc
ns
neg
sampl
manifest
symptom
report
rang
day
two
week
report
symptom
compar
ebc
posit
patient
ns
posit
patient
posit
ns
group
experienc
shiver
muscl
pain
wherea
symptom
indic
patient
ebc
posit
group
group
fever
headach
water
eye
stuf
nose
frequent
sneez
sore
throat
cough
report
volunt
diagnos
pathogen
particip
studi
sinc
test
sampl
viral
pathogen
exclud
possibl
neg
ns
posit
bacteria
pathogen
caus
respiratori
ill
recent
one
studi
report
detect
rate
influenza
ebc
rang
detect
rate
report
respiratori
virus
gener
studi
limit
number
patient
describ
markedli
higher
sensit
higher
percentag
may
due
low
number
particip
subject
includ
remark
studi
report
higher
detect
rate
use
collect
mask
studi
use
report
compar
find
face
mask
consist
electret
trap
virus
base
perman
charg
fibr
addit
teflon
filter
pore
retain
larger
particl
possibl
lower
detect
rate
partli
explain
fact
manufactur
polypropylen
possess
viru
attract
filter
featur
like
aforement
materi
qrtpcr
develop
lu
cowork
detect
rv
allow
assess
viral
load
present
ebc
sampl
also
ns
viral
titer
remain
undetermin
probabl
due
limit
sensit
assay
diagnosi
sensit
method
might
necessari
detect
respiratori
virus
present
ebc
sinc
unpredict
dilut
viral
particl
specimen
recent
nest
qrtpcr
assay
develop
allow
sensit
detect
virus
aerosol
also
persondepend
factor
number
particl
produc
exhal
volum
age
patient
suggest
play
import
role
exhal
viral
particl
particip
recruit
studi
fabian
cowork
year
age
older
hospit
children
much
higher
rate
viru
posit
sampl
report
studi
major
volunt
year
old
two
children
less
year
elderli
peopl
year
includ
one
children
test
posit
infa
ns
infect
confirm
ebc
influenza
exhal
gener
rate
influenza
rna
copi
per
minut
predict
quantifi
viru
aerosol
impact
remov
teflon
filter
collect
mask
use
combin
ecov
allow
registr
addit
ventil
paramet
breath
frequenc
exhal
volum
way
number
rna
copi
ebc
quantifi
amount
viral
particl
exhal
per
litr
per
minut
estim
unfortun
abl
predict
viru
gener
rate
infb
sinc
viral
load
remain
undetermin
although
invent
new
promis
method
ebc
collect
appear
appropri
diagnosi
respiratori
infect
nonetheless
method
may
provid
altern
current
sampl
procur
epidemiolog
studi
circul
virus
techniqu
also
confirm
observ
virus
abl
dissemin
normal
breath
particularli
rv
addit
ebc
collect
patient
respiratori
infect
may
investig
biomark
pattern
calv
experiment
infect
bovin
rsv
increas
leukotrien
b
indic
oxid
stress
observ
increas
level
also
associ
develop
bronchial
hyperrespons
human
transient
elev
h
level
observ
common
cold
infect
marker
return
baselin
valu
volunt
recov
infect
h
also
recogn
interest
marker
asthma
associ
chronic
lower
airway
inflamm
infa
infect
volunt
increas
co
level
observ
upper
respiratori
infect
observ
might
impli
co
indic
airway
inflamm
repres
one
host
defenc
mechan
viral
infect
therefor
better
identif
biomark
signatur
condens
individu
experienc
viral
infect
might
impli
interest
find
toward
identif
marker
reflect
inflamm
antivir
protect
may
contribut
biomark
profil
establish
diseas
like
asthma
copd
viral
infect
suggest
trigger
exacerb
symptom
